CHRS - Coherus BioSciences - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

CHRS is currently covered by 11 analysts with an average price target of $9.74. This is a potential upside of $8.73 (864.36%) from yesterday's end of day stock price of $1.01.

Coherus BioSciences's activity chart (see below) currently has 76 price targets and 88 ratings on display. The stock rating distribution of CHRS is 84.62% BUY and 15.38% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 9.29% with an average time for these price targets to be met of 83.62 days.

Highest price target for CHRS is $11, Lowest price target is $1.5, average price target is $7.85.

Most recent stock forecast was given by DOUGLAS TSAO from HC WAINWRIGHT on 23-Jan-2025. First documented stock forecast 27-Jul-2016.

Currently out of the existing stock ratings of CHRS, 33 are a BUY (84.62%), 6 are a HOLD (15.38%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$7

1 months 8 days ago
(23-Jan-2025)

0/14 (0%)

$5.29 (309.36%)

Hold

$1.5

$0.39 (35.14%)

$7

6 months 15 days ago
(16-Aug-2024)

1/3 (33.33%)

$0.24 (19.05%)

109

Buy

$7

$5.89 (530.63%)

$7

9 months 18 days ago
(13-May-2024)

0/5 (0%)

$4.91 (234.93%)

Buy

$11

$9.89 (890.99%)

11 months 11 days ago
(20-Mar-2024)

0/4 (0%)

$8.52 (343.55%)

Hold

$22

1 years 3 months 23 days ago
(08-Nov-2023)

3/8 (37.5%)

$7.72 (54.06%)

181

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is CHRS (Coherus BioSciences) average time for price targets to be met?

On average it took 83.62 days on average for the stock forecasts to be realized with a an average price target met ratio 9.29

Which analyst has the current highest performing score on CHRS (Coherus BioSciences) with a proven track record?

JASON MCCARTHY

Which analyst has the most public recommendations on CHRS (Coherus BioSciences)?

Jason Mccarthy works at MAXIM GROUP and has 2 price targets and 2 ratings on CHRS

Which analyst is the currently most bullish on CHRS (Coherus BioSciences)?

Michael Ulz with highest potential upside - $28.89

Which analyst is the currently most reserved on CHRS (Coherus BioSciences)?

Douglas Tsao with lowest potential downside - -$0

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?